Colección SciELO Chile

Departamento Gestión de Conocimiento, Monitoreo y Prospección
Consultas o comentarios: productividad@anid.cl
Búsqueda Publicación
Búsqueda por Tema Título, Abstract y Keywords



Predicting change in diagnosis from major depression to bipolar disorder after antidepressant initiation
Indexado
WoS WOS:000571024400001
Scopus SCOPUS_ID:85090958738
DOI 10.1038/S41386-020-00838-X
Año 2021
Tipo artículo de investigación

Citas Totales

Autores Afiliación Chile

Instituciones Chile

% Participación
Internacional

Autores
Afiliación Extranjera

Instituciones
Extranjeras


Abstract



We aimed to develop and validate classification models able to identify individuals at high risk for transition from a diagnosis of depressive disorder to one of bipolar disorder. This retrospective health records cohort study applied outpatient clinical data from psychiatry and nonpsychiatry practice networks affiliated with two large academic medical centers between March 2008 and December 2017. Participants included 67,807 individuals with a diagnosis of major depressive disorder or depressive disorder not otherwise specified and no prior diagnosis of bipolar disorder, who received at least one of the nine antidepressant medications. The main outcome was at least one diagnostic code reflective of a bipolar disorder diagnosis within 3 months of index antidepressant prescription. Logistic regression and random forests using diagnostic and procedure codes as well as sociodemographic features were used to predict this outcome, with discrimination and calibration assessed in a held-out test set and then a second academic medical center. Among 67,807 individuals who received at least one antidepressant medication, 925 (1.36%) subsequently received a diagnosis of bipolar disorder within 3 months. Models incorporating coded diagnoses and procedures yielded a mean area under the receiver operating characteristic curve of 0.76 (ranging from 0.73 to 0.80). Standard supervised machine learning methods enabled development of discriminative and transferable models to predict transition to bipolar disorder. With further validation, these scores may enable physicians to more precisely calibrate follow-up intensity for high-risk patients after antidepressant initiation.

Revista



Revista ISSN
Neuropsychopharmacology 0893-133X

Métricas Externas



PlumX Altmetric Dimensions

Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:

Disciplinas de Investigación



WOS
Neurosciences
Psychiatry
Pharmacology & Pharmacy
Scopus
Sin Disciplinas
SciELO
Sin Disciplinas

Muestra la distribución de disciplinas para esta publicación.

Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.

Colaboración Institucional



Muestra la distribución de colaboración, tanto nacional como extranjera, generada en esta publicación.


Autores - Afiliación



Ord. Autor Género Institución - País
1 Pradier, Melanie F. Mujer Harvard John A. Paulson School of Engineering and Applied Sciences - Estados Unidos
Harvard A John Paulson Sch Engn & Appl Sci - Estados Unidos
2 Hughes, Michael C. Hombre Tufts University - Estados Unidos
Tufts Univ - Estados Unidos
3 McCoy, Thomas H. Hombre Massachusetts General Hospital - Estados Unidos
Harvard Medical School - Estados Unidos
MASSACHUSETTS GEN HOSP - Estados Unidos
Harvard Med Sch - Estados Unidos
4 BARROILHET-DIEZ, SERGIO ANDRES Hombre Massachusetts General Hospital - Estados Unidos
Harvard Medical School - Estados Unidos
Tufts University School of Medicine - Estados Unidos
Hospital Clínico de la Universidad de Chile - Chile
MASSACHUSETTS GEN HOSP - Estados Unidos
Harvard Med Sch - Estados Unidos
Tufts Univ - Estados Unidos
Universidad de Chile - Chile
Hospital Clínico Universidad de Chile - Chile
5 Doshi-Velez, Finale - Harvard John A. Paulson School of Engineering and Applied Sciences - Estados Unidos
Harvard A John Paulson Sch Engn & Appl Sci - Estados Unidos
6 Perlis, Roy H. Hombre Massachusetts General Hospital - Estados Unidos
Harvard Medical School - Estados Unidos
MASSACHUSETTS GEN HOSP - Estados Unidos
Harvard Med Sch - Estados Unidos

Muestra la afiliación y género (detectado) para los co-autores de la publicación.

Financiamiento



Fuente
National Heart, Lung, and Blood Institute
National Institute of Mental Health
National Human Genome Research Institute
National Institute on Aging
NHLBI
NIMH
Brain and Behavior Research Foundation
Harvard Data Science Initiative
Harvard
National Institute of Aging
Stanley Center for Psychiatric Research, Broad Institute
Broad Institute
Telefonica Alfa
NHGRI
Harvard SEAS
Oracle Labs
Stanley Center at the Broad Institute
Department of Communications, Energy and Natural Resources, Ireland
Oracle

Muestra la fuente de financiamiento declarada en la publicación.

Agradecimientos



Agradecimiento
This work was funded by Oracle Labs, Harvard SEAS, the Harvard Data Science Initiative, and a grant from the National Institute of Mental Health (grant no. 1R01MH106577). The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. RHP holds equity in Psy Therapeutics and Outermost Therapeutics; serves on the scientific advisory boards of Genomind and Takeda; and consults to RID Ventures. RHP receives research funding from NIMH, NHLBI, NHGRI, and Telefonica Alfa. RHP is an associate editor for JAMA Network Open. THM receives research funding from the Stanley Center at the Broad Institute, the Brain and Behavior Research Foundation, National Institute of Aging, and Telefonica Alfa. FDV consults for Davita Kidney Care and Google Health. The other authors have no disclosures to report.
This work was funded by Oracle Labs, Harvard SEAS, the Harvard Data Science Initiative, and a grant from the National Institute of Mental Health (grant no. 1R01MH106577). The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. RHP holds equity in Psy Therapeutics and Outermost Therapeutics; serves on the scientific advisory boards of Genomind and Takeda; and consults to RID Ventures. RHP receives research funding from NIMH, NHLBI, NHGRI, and Telefonica Alfa. RHP is an associate editor for JAMA Network Open. THM receives research funding from the Stanley Center at the Broad Institute, the Brain and Behavior Research Foundation, National Institute of Aging, and Telefonica Alfa. FDV consults for Davita Kidney Care and Google Health. The other authors have no disclosures to report.

Muestra la fuente de financiamiento declarada en la publicación.